Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Natco Pharma and Dr. Reddy's Laboratories are eyeing blockbuster drug–Novo Nordisk’s breakout star Semaglutide, sold under ...

Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...